News
Click here for news in Danish.
December 31, 2009 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/S as of 31 December 2009December 21, 2009 | Company Announcements
Bavarian Nordic A/S – Notice convening Extraordinary General MeetingDecember 18, 2009 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held 18 December 2009December 18, 2009 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchDecember 18, 2009 | Company Announcements
Bavarian Nordic Updates on Business Activities and Financial OutlookDecember 01, 2009 | Company Announcements
Bavarian Nordic is Planning a Rights Issue of DKK 250-300 Million. The Company Has Convened an Extraordinary General MeetingDecember 01, 2009 | Company Announcements
Bavarian Nordic A/S – Notice convening Extraordinary General MeetingNovember 30, 2009 | Company Announcements
Bavarian Nordic will file for market approval for IMVAMUNE® in CanadaNovember 26, 2009 | Company Announcements
Bavarian Nordic A/S issues Financial Calendar for 2010November 17, 2009 | Company Announcements
US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE® Smallpox VaccineNovember 11, 2009 | Company Announcements
Bavarian Nordic Enters Conditional Agreement for the Acquisition of Shares and Buy Back of Stock Options in its Subsidiary BN ImmunoTherapeutics Inc. in Order to Obtain 100% Ownership of the SubsidiaryNovember 11, 2009 | Company Announcements
Bavarian Nordic A/S – Interim Report for the period 1 January to 30 September 2009September 21, 2009 | Company Announcements
New and interesting PROSTVAC™ data indicate broad therapeutic use in metastatic prostate cancerSeptember 18, 2009 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchSeptember 15, 2009 | Company Announcements
Bavarian Nordic has signed contract with an EU country for the delivery of IMVAMUNE®August 31, 2009 | Company Announcements
Bavarian Nordic rejects claim from Helmholtz Zentrum MünchenAugust 28, 2009 | Company Announcements
Bavarian Nordic A/S – Interim Report for the period 1 January to 30 June 2009August 24, 2009 | Company Announcements
Bavarian Nordic in negotiations with the US authorities for the further development of IMVAMUNE®July 01, 2009 | Company Announcements
New Review on PROSTVAC™ published by key Investigators from NCIMay 30, 2009 | Company Announcements
PROSTVAC™ data presented at the ASCO Meeting demonstrates the potential for significant increases in life expectancy in late-stage prostate cancerMay 18, 2009 | Company Announcements
Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 18 May 2009May 09, 2009 | Company Announcements
The court supports Bavarian Nordic’s decision to start patent infringement case against Oxford BioMedicaApril 30, 2009 | Company Announcements
Bavarian Nordic A/S – Notice convening Extraordinary General MeetingApril 27, 2009 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held 27 April 2009April 27, 2009 | Company Announcements
Bavarian Nordic A/S – Interim Report for the period 1 January to 31 March 2009